CORCEPT THERAPEUTICS INC
CORTNASDAQ🏆 #660 by market capEarnings Nov 3US Equity
$111.86▼ $2.32 (−2.07%)
Market closed · at close1h—
24h▼ 2.1%
7d—
14d—
30d—
1y—
🏦Market Cap
$12.09B
Mid Cap
📈Revenue Growth (YoY)
+16.0%
Healthy
📊Gross Margin
98.3%
High
💵FCF Margin
14.9%
Healthy
⚖️P/S Ratio
14.8x
Expensive
Otter Score
50
Weak
📊
Analyst Ratings
Price
$111.86
Total
26
Raised
2
Lowered
8
Avg PT
$117.60
H / L
$165 / $50
| Institution | Action | Rating | Date |
|---|---|---|---|
Piper Sandler | Reiterated | Overweight | 2026-07-30 |
HC Wainwright & Co. | Reiterated | Buy | 2026-07-30 |
Canaccord Genuity | Reiterated | Buy | 2026-07-30 |
Wolfe Research | Downgraded | Peer Perform → Underperform | 2026-07-27 |
UBS | Upgraded | Neutral → Buy | 2026-05-13 |
Truist Securities | Reiterated | Buy | 2025-03-31 |
SVB Leerink | Reiterated | Market Perform → Perform | 2023-04-11 |
Jefferies | Downgraded | Buy → Hold | 2023-02-15 |
Cantor Fitzgerald | Reiterated | Neutral | 2020-02-21 |
H.C. Wainwright | Reiterated | Buy | 2019-09-06 |
B. Riley FBR | Reiterated | Buy | 2018-08-13 |
B. Riley Securities | Reiterated | Buy | 2018-08-13 |
Stifel Nicolaus | Downgraded | Buy → Hold | 2018-05-31 |
Stifel | Downgraded | Buy → Hold | 2018-05-31 |
Ladenburg Thalmann | Reiterated | Buy | 2017-02-02 |
Janney Capital | Reiterated | Buy | 2015-12-17 |
FBR Capital | Reiterated | Outperform | 2015-04-21 |
PiperJaffray | Upgraded | Neutral → Overweight | 2015-03-11 |
Brinson Patrick | Reiterated | Market Outperform → Outperform | 2014-04-01 |
Janney Montgomery Scott | Downgraded | Buy → Neutral | 2013-08-09 |
Credit Suisse | Downgraded | Outperform → Neutral | 2013-08-09 |
Cowen & Co. | Downgraded | Outperform → Neutral | 2012-12-10 |
Oppenheimer | Downgraded | Outperform → Market Perform | 2012-11-02 |
B of A Securities | Reiterated | Underperform | 2012-11-01 |
Bank of America | Reiterated | Underperform | 2012-11-01 |
ThinkEquity | Reiterated | Buy | 2012-06-29 |
One row per institution, most recent rating